HTAs published by Scottish Health Technology Group in the second quarter of 2021

03

Sep 2021

The Scottish Health Technologies Group (SHTG) is a national health technology assessment (HTA) agency providing advice to NHSScotland on the use of new and existing health technologies (excluding medicines), likely to have a significant impact on healthcare. NHSScotland is required to consider SHTG advice.

In the second quarter of 2021, SHTG published only one assessment on detection of paroxysmal atrial fibrillation in patients with newly diagnosed ischaemic stroke.

The key research question was the most clinically and cost-effective strategy to detect paroxysmal atrial fibrillation (PAF) in patients with newly diagnosed ischaemic stroke who are selected to have prolonged electrocardiogram (ECG) monitoring. One of the additional questions was comparative clinical and cost-effectiveness of ambulatory ECG monitoring technologies (Holter, event recorder, patch technologies) in the detection of PAF in patients with newly diagnosed ischaemic stroke selected to have prolonged ECG monitoring.

It was stated that there is insufficient evidence to make clear conclusions on the comparative clinical and cost-effectiveness of ambulatory ECG monitoring technologies. Drawing conclusions is challenging as the technology in this area is rapidly evolving. For patch technologies, the existing evidence is inconclusive and requires validation in larger diagnostic studies. NICE medical technologies guidance states that patch technology Zio XT is recommended (with caveats) as an option for people with suspected cardiac arrhythmias who would benefit from ambulatory ECG monitoring for longer than 24 hours. Evidence from randomized controlled trials comparing electronic loop recorders (ELRs) and ambulatory Holters in people with cryptogenic stroke is insufficient to distinguish the relative clinical effectiveness of the different devices.

There is insufficient evidence to define the optimal duration of long-term monitoring. Advice from Canada (CADTH, 2016) recommended seven days of continuous ambulatory cardiac monitoring with either a Holter monitor or external loop recorder for patients who have been discharged from the hospital after a stroke or TIA and who did not undergo continuous cardiac monitoring while in hospital.

The National Planning atrial fibrillation group will consider this SHTG assessment to inform more consistent practice across health boards.

See the full details in English here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

21

Sep 2021

In August 2021, the mini-HTA evaluation of the robot-assisted percutaneous coronary intervention was released. The method was described as safe and effective. After the introduction into the clinical practice, the method should be followed up for two years with a sufficient number of procedures to understand the real benefit. All procedures are to be registered in the Norwegian Registry for Invasive Cardiology.

Read more

17

Sep 2021

In mid-August 2021, the Finnish Coordinating Center for Health Technology Assessment announced the release of the four accomplished rapid hospital assessments (HTA) performed by the Helsinki University Hospital. The accomplished rapid HTAs concern the cardiovascular, peripheral vascular, and endoscopy technology groups.

Read more

16

Sep 2021

On August 17, 2021, the National Institute of Public Health released a rapid HTA report on the evaluation of PD-L1 assays in urothelial carcinoma commissioned by the Ordering Forum. This assessment does not provide any conclusions on the effectiveness of various treatment strategies in the treatment of urothelial carcinoma in adults.

Read more

15

Sep 2021

On August 19, 2021, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the MammaPrint and EndoPredict tests for various reasons.

Read more

10

Sep 2021

On August 31, 2021, NHSX published a set of guidelines for digitized healthcare, including the Unified Tech Fund (UTF) prospectus, which seeks to simplify and consolidate the process for accessing technology funding. The UTF brings together several national technology funds. This amounts to £680 million available to NHS organizations throughout the financial year 2021 to 2022. The applications submission is open from August 31, 2021.

Read more